Etravirine: 4 agencies, 2009–2021
This page collects every recorded health technology assessment decision for one molecule across the agencies in our archive, and compares them. The comparison is the point: each agency publishes its own verdict, none publishes how that verdict sits against the others.
What the record shows
The file has been open for more than a decade: 12.7 years separate the first record, 7 Jan 2009 at HAS (France), from the most recent, 30 Sep 2021 at AWMSG (Wales).
SMC (Scotland) changed its position: not recommended on 9 Feb 2009, restricted by 9 Sep 2013, after a resubmission.
No assessment is on file from PBAC (Australia), TLV (Sweden), CIPM (Spain) and G-BA (Germany), each among the eight highest-volume agencies here.
Nothing has been added since 2021; on this evidence the file is dormant.
4 distinct indication wordings are recorded for etravirine by the agencies that label one in English (AWMSG and SMC).
The systems moved almost together: all 4 agencies opened a file on etravirine within a year of one another, starting with HAS (France) on 7 Jan 2009.
The record arrives in waves: 3 separate years each carry two or more decisions, spread across 6 years in total.
3 of the 4 agencies here assessed etravirine more than once, HAS (France) most often at 6 entries — repeat review is the norm for this molecule rather than the exception.
Coverage is narrow: only 4 of the 18 agencies here have assessed etravirine.
The full ledger for etravirine reads 6 recommended, 5 other, 1 restricted and 1 not assessed, with 1 in other categories.
Decisions on file
| Agency | Date | Indication as recorded | Outcome | Source |
|---|---|---|---|---|
| AWMSG (Wales) | 30 Sep 2021 | In combination with a boosted protease inhibitor and other antiretroviral medicinal products, for the treatment of human… | recommended (licence extension for paediatric use) | source |
| HAS (France) | 4 Nov 2020 | Indication extension | SMR substantial · ASMR III | source |
| HAS (France) | 6 Nov 2013 | Listing (Transparency Committee) | ASMR III | source |
| SMC (Scotland) | 9 Sep 2013 | In combination with a boosted protease inhibitor and other antiretroviral medicinal products, for the treatment of human immunodeficiency virus type 1 (HIV-1) infection i… | accepted (restricted) | source |
| PHARMAC (New Zealand) | 12 Nov 2009 | treatment of HIV/AIDS | PTAC advice: No Formal Recommendation · decision reached | source |
9 further decisions for etravirine, across 3 agencies, are not shown here. They link to 6 further source documents.
Related molecules
- sofosbuvir — same ATC class J05A — Antivirals
- letermovir — same ATC class J05A — Antivirals
- raltegravir — same ATC class J05A — Antivirals
- cabotegravir — same ATC class J05A — Antivirals
- tenofovir — same ATC class J05A — Antivirals
- darunavir — same ATC class J05A — Antivirals
Coverage: 14 decisions for etravirine from 4 agencies, 2009 to 2021. Data to 7 Sep 2026. ATC class J05A — Antivirals. How this page is produced. Compiled by Altima Partners; queries: sales@altimapartners.co.uk.